News InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Related Continue Reading Previous Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsNext Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors Related Stories AI Engineering Enterprise News Programming Software Development Mphasis Unveils Mphasis NeoCruxTM and Mphasis NeoZetaTM: A Powerful Duo for AI-Driven Software Engineering and Enterprise Modernization News J.D. Power-GlobalData U.S. Automotive Forecast for July 2024 News Franklin Resources, Inc. Announces Third Quarter Results News Tango Announces Launch of Tango Occupancy News John Snow Labs Launches Automated Testing for Responsible AI—the First No-Code Tool to Test and Evaluate Custom Language Models News Tabnine Unveils Second Generation Protected LLM to Keep AI Workloads Private, Protected, and Compliant
